EA201892443A1 - Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови - Google Patents

Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови

Info

Publication number
EA201892443A1
EA201892443A1 EA201892443A EA201892443A EA201892443A1 EA 201892443 A1 EA201892443 A1 EA 201892443A1 EA 201892443 A EA201892443 A EA 201892443A EA 201892443 A EA201892443 A EA 201892443A EA 201892443 A1 EA201892443 A1 EA 201892443A1
Authority
EA
Eurasian Patent Office
Prior art keywords
blood cells
antibodies against
pharmaceutical compositions
clinical use
against antigen
Prior art date
Application number
EA201892443A
Other languages
English (en)
Russian (ru)
Inventor
Марк Р. Х. Кребс
Дэвид Дай
Шантану Сьюл
Даниа Рабах
Дэвид Мартин
Original Assignee
Байоджен Ма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Ма Инк. filed Critical Байоджен Ма Инк.
Publication of EA201892443A1 publication Critical patent/EA201892443A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EA201892443A 2016-04-28 2017-04-27 Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови EA201892443A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662328959P 2016-04-28 2016-04-28
PCT/US2017/029802 WO2017189827A1 (en) 2016-04-28 2017-04-27 Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies

Publications (1)

Publication Number Publication Date
EA201892443A1 true EA201892443A1 (ru) 2019-04-30

Family

ID=58672794

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892443A EA201892443A1 (ru) 2016-04-28 2017-04-27 Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови

Country Status (16)

Country Link
US (2) US20190284281A1 (enExample)
EP (1) EP3448425A1 (enExample)
JP (3) JP7045327B2 (enExample)
KR (5) KR20220028150A (enExample)
CN (2) CN116850282A (enExample)
AU (2) AU2017258191B2 (enExample)
BR (1) BR112018072125A2 (enExample)
CA (1) CA3022116A1 (enExample)
CO (1) CO2018012506A2 (enExample)
EA (1) EA201892443A1 (enExample)
IL (2) IL262514B2 (enExample)
MA (1) MA44763A (enExample)
MX (3) MX2018012945A (enExample)
NZ (2) NZ787392A (enExample)
PH (1) PH12018502278A1 (enExample)
WO (1) WO2017189827A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3672981A4 (en) * 2017-08-22 2021-09-15 Biogen MA Inc. PROCESSES FOR PURIFYING ANTIBODIES PRESENTING REDUCED AGGREGATES WITH HIGH MOLECULAR WEIGHT
EP4559485A3 (en) 2018-07-19 2025-08-06 Ichnos Sciences S.A. Liquid antibody formulation
KR200494676Y1 (ko) 2020-08-04 2021-12-01 (주) 티나인 버튼식 헤어 염색기
IL303279A (en) 2020-12-03 2023-07-01 Biogen Ma Inc Methods of treating cutaneous lupus erythematosus and systemic lupus erythematosus
EP4385525A1 (en) 2021-08-09 2024-06-19 Inventera Inc. Nanostructure excreted in urine through kidney without being phagocytosed and/or metabolized by macrophage after in vivo injection
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥（蘇州）有限公司 抗ｂｄｃａ２抗體及其用途
WO2024140838A1 (zh) * 2022-12-28 2024-07-04 映恩生物制药（苏州）有限公司 抗bdca2抗体-药物偶联物及其用途
WO2025067469A1 (zh) * 2023-09-28 2025-04-03 南京维立志博生物科技股份有限公司 Bdca2单克隆抗体及其和taci组成的融合蛋白及其方法和用途
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2335725T3 (en) * 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
MX363407B (es) * 2012-12-10 2019-03-22 Biogen Ma Inc Anticuerpos del antigeno 2 de celulas dendriticas anti-sangre y usos de los mismos.

Also Published As

Publication number Publication date
IL262514B1 (en) 2025-08-01
CA3022116A1 (en) 2017-11-02
MA44763A (fr) 2019-03-06
KR20190002563A (ko) 2019-01-08
PH12018502278A1 (en) 2019-09-09
JP2019520316A (ja) 2019-07-18
KR20220028150A (ko) 2022-03-08
KR20240159012A (ko) 2024-11-05
JP2024038308A (ja) 2024-03-19
US20250289895A1 (en) 2025-09-18
IL262514A (en) 2018-12-31
IL262514B2 (en) 2025-12-01
US20190284281A1 (en) 2019-09-19
KR102366547B1 (ko) 2022-02-23
NZ747504A (en) 2025-08-29
EP3448425A1 (en) 2019-03-06
WO2017189827A1 (en) 2017-11-02
MX2023008075A (es) 2023-07-18
JP7045327B2 (ja) 2022-03-31
NZ787392A (en) 2025-08-29
AU2017258191B2 (en) 2024-06-13
CN109475623A (zh) 2019-03-15
BR112018072125A2 (pt) 2019-03-19
JP2022084782A (ja) 2022-06-07
CN109475623B (zh) 2023-05-26
MX2025000037A (es) 2025-02-10
CN116850282A (zh) 2023-10-10
CO2018012506A2 (es) 2018-12-14
AU2017258191A1 (en) 2018-11-15
MX2018012945A (es) 2019-03-06
KR20240033168A (ko) 2024-03-12
IL321561A (en) 2025-08-01
KR20250088784A (ko) 2025-06-17
AU2024203240A1 (en) 2024-06-13

Similar Documents

Publication Publication Date Title
EA201892443A1 (ru) Фармацевтические композиции и режимы дозирования для клинического использования антител против антигена 2 дендритных клеток крови
AR110645A1 (es) Anticuerpos anti-hla-g y uso de los mismos
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
BR112018068748A2 (pt) composto, composição farmacêutica e de vacina, métodos para indução ou promoção de uma resposta imunológica, para tratamento de câncer, de doenças infecciosas, de distúrbios imunológicos e de doenças imunológicas e para tratamento ou prevenção de uma doença, e, uso de um composto
CY1122060T1 (el) Συνδυαστικη θεραπευτικη χρηση αντισωματων και ενδογλυκοσιδασεων
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
MX375752B (es) Inhibidores de tirosina quinasa de bruton.
EA201891186A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201890006A1 (ru) Применение экзосом для лечения болезни
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201790239A1 (ru) Молекула-носитель для антигенов
ZA202103867B (en) Tubulysins and protein-tubulysin conjugates
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
EA201991951A1 (ru) Низковязкие высококонцентрированные составы на основе эволокумаба и способы их получения
EA201791067A1 (ru) Способы лечения субъектов с синдромом прадера-вилли или синдромом смита-магениса
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
MX2018005226A (es) Formulaciones de anticuerpo anti-factor d.
AR109279A1 (es) Anticuerpos anti plazomicina y métodos de uso de los mismos
MX390441B (es) Formulaciones liquidas de fosfaplatino.
EA202192418A1 (ru) Способы лечения al-амилоидоза